Angiogenic T (Tang) cells are mediators of vascular repair, and are characterized by surface expression of CXCR4. This receptor for stromal cell‐derived factor‐1α (SDF‐1α) is cleaved by dipeptidyl peptidase‐4 (DPP‐4). Tang cell levels were investigated in people with type 2 diabetes mellitus (T2DM) compared with matched healthy controls and after treatment with the DPP‐4 inhibitor Linagliptin. People with T2DM were randomized to 5 mg/day Linagliptin (n = 20) or placebo (n = 21) for 26 weeks. Tang cell frequency was identified in peripheral blood mononuclear cells (CD3⁺CD31⁺CXCR4⁺) and levels of endothelial progenitor cells (EPCs) (CD34⁺CD133⁺KDR⁺) were also assessed in whole blood. Circulating Tang cell levels were significantly lower in people with T2DM compared with the healthy control group. SDF‐1α levels increased significantly in Linagliptin‐treated people with T2DM compared to placebo, and a trend was observed in change of Tang cell levels, while EPC count did not change. In conclusion, circulating Tang cell levels were considerably lower in people with T2DM, while a trend was observed in recruitment of Tang cells after 26 weeks of treatment with Linagliptin. These data suggest that DPP‐4 inhibitors may potentially exert beneficial effects on bone marrow‐driven vascular repair.

中文翻译：

---

2型糖尿病患者的血管生成性T细胞减少，并被二肽基肽酶4抑制剂Linagliptin募集：这是一项来自随机，安慰剂对照试验的亚分析（RELEASE研究）。

血管生成T（Tang）细胞是血管修复的介质，其特征是CXCR4的表面表达。这种基质细胞衍生因子-1α（SDF-1α）的受体被二肽基肽酶-4（DPP-4）裂解。在与DPP-4抑制剂利格列汀治疗后相比较的健康对照组中，比较了2型糖尿病（T2DM）患者的Tang细胞水平。患有T2DM的患者被随机分配到5 mg /天的利格列汀（n = 20）或安慰剂（n = 21）26周。在外周血单核细胞（CD3 ⁺ CD31 ⁺ CXCR4 ⁺）和内皮祖细胞（EPC）（CD34 ⁺ CD133 ⁺ KDR ⁺）也进行了全血评估。与健康对照组相比，T2DM患者的循环唐细胞水平显着降低。与安慰剂相比，经利格列汀治疗的2型糖尿病患者的SDF-1α水平显着增加，并且Tang细胞水平的变化趋势得以观察，而EPC计数却没有变化。总之，T2DM患者的循环唐细胞水平显着降低，而使用利格列汀治疗26周后，观察到唐细胞募集的趋势。这些数据表明，DPP-4抑制剂可能对骨髓驱动的血管修复产生有益作用。